Purpose Report final data from adolescent (12–< 18 years) and adult (≥ 18 years) patients
from PROVE (NCT03208660), a multicenter, retrospective, non-interventional, Phase IV …

Perampanel (PER) is a new antiseizure medication that inhibits the α-amino-3-hydroxy-5-
methyl-4-isoxazole-propionic acid (AMPA) class of glutamate receptors. It is important for …

This systematic review was conducted to reveal the cognitive effects of perampanel (PER)
as assessed by objective standardized neuropsychological measures in patients with …

Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor antagonist, is a once-daily oral anti-seizure medication (ASM) for focal-onset …

Perampanel (PER) is a novel antiepileptic compound that decreases neuronal excitability by
modulating glutamatergic transmission through selective noncompetitive blockade of AMPA …

Perampanel (PER) is a novel antiepileptic drug recently introduced for the adjunctive
treatment in epilepsy patients aged 12 years or older with partial-onset seizures with or …

Background: The aim of this study was to analyse registry data of seizure outcome and
adverse events (AEs) for perampanel as add-on therapy in patients with focal epilepsy since …

This study determined the 24-month outcomes of perampanel treatment in children and
adolescents with epilepsy. The percentage of≥ 50% responders was 47.3%(139/294) at 12 …

Objective To assess the effectiveness and safety/tolerability of perampanel (PER) in people
with epilepsy (PWE) treated in everyday clinical practice for focal and generalized seizures …

Objective To analyze the effectiveness and tolerability of perampanel across different
seizure types in routine clinical care of patients with idiopathic generalized epilepsy (IGE) …